CaRi-Heart® for Coronary Artery Disease

(CARE-CCTA Trial)

This trial aims to determine if a software tool called CaRi-Heart® can help doctors better understand and treat coronary artery disease. The tool uses AI to analyze images from routine heart scans to measure inflammation in the heart's arteries. This analysis might enable doctors to make more informed decisions about managing heart disease earlier. Individuals undergoing Coronary CT Angiography (CCTA) as part of their normal care, without a history of heart surgery, are well-suited for this trial. As an unphased trial, this study offers participants the chance to contribute to cutting-edge research that could enhance heart disease management for future patients.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Previous studies have used CaRi-Heart® analysis to predict heart disease risk by examining inflammation in the heart's arteries. This tool employs artificial intelligence (AI) to analyze images from standard heart scans. The analysis is non-invasive, as it does not involve surgery or entering the body. No reports indicate harm, as it only examines existing images. This makes it a safe option for those considering joining trials.¹²³⁴⁵

Researchers are excited about the CaRi-Heart® Analysis because it offers a new way to assess coronary artery disease by focusing on coronary inflammation. Unlike standard treatments that mainly look at narrowing or blockages in arteries, this technique uses advanced software to analyze heart scans, providing unique insights into inflammation that might lead to better and more personalized treatment decisions. This innovation could help doctors identify patients at higher risk of heart problems earlier, potentially improving outcomes and tailoring care more effectively.

Studies have shown that CaRi-Heart® analysis can predict a person's risk of a deadly heart event over the next eight years. This technology uses AI to detect inflammation in the heart's arteries, aiding doctors in identifying individuals at higher risk for heart problems. In this trial, participants will undergo standard CCTA with CaRi-Heart® software analysis to assess coronary inflammation and evaluate its impact on clinical decision-making. Research suggests that using CaRi-Heart® could reduce deaths from heart issues by 12% and decrease heart attacks by 11%. This approach may help doctors make more informed treatment decisions for heart disease, potentially improving patient health outcomes.⁵⁶⁷⁸⁹